The mechanism of Sphk2 inhibitors in leukemia is mainly based on increasing autophagic death, as seen for example in T cell-acute lymphocytic leukemia [41, 42], or a decrease in cell proliferation and induction of apoptosis in multiple myeloma cells [43]. Here, SPHK2 is linked to plasma cell myeloma.